Canonica G W, Pesce G, Ruffoni S, Buscaglia S, Boero F, Jing G, Rihoux J P, Ciprandi G
Allergy and Clinical Immunology Service, Department of Internal Medicine Genoa, Italy.
Ann Allergy. 1992 Mar;68(3):251-4.
Antihistamines are frequently employed in the treatment of allergic rhinitis and urticaria-angioedema syndrome. We analyzed the in vitro effects of cetirizine on the immune response. To this end the proliferation of peripheral mononuclear cells induced by mitogen and by -CD3, -CD2, or -CD28 monoclonal antibodies has been studied. Since the plasma peak of cetirizine following ingestion of 10 mg is about 1 microgram/mL, the drug was tested in the cultures at the concentration of 0.1, 1, or 10 micrograms/mL. No influence of cetirizine on T cell proliferation was detected. We also evaluated the effect of cetirizine on the expression of the following markers expressed by T cells upon activation: lymphocyte markers ICAM-1, HLA-DR, and CD25 surface expression, alpha-1-acid glycoprotein has been also studied. There was no effect of cetirizine on the investigated immunologic parameters; these data acquire clinical relevance when related to previous reports showing a depression of the immunologic response exerted by other compounds such as ketotifen and theophylline and when related to the recent data about the modulation of ICAM-1 expression on eosinophils by cetirizine. Cetirizine does not affect ICAM-1 expression of lymphocyte membrane.
抗组胺药常用于治疗变应性鼻炎和荨麻疹 - 血管性水肿综合征。我们分析了西替利嗪对免疫反应的体外作用。为此，研究了丝裂原以及抗 CD3、抗 CD2 或抗 CD28 单克隆抗体诱导的外周单核细胞增殖情况。由于摄入 10 毫克西替利嗪后的血浆峰值约为 1 微克/毫升，因此在培养物中以 0.1、1 或 10 微克/毫升的浓度对该药物进行了测试。未检测到西替利嗪对 T 细胞增殖有影响。我们还评估了西替利嗪对 T 细胞活化后表达的以下标志物的影响：淋巴细胞标志物 ICAM - 1、HLA - DR 和 CD25 表面表达，还研究了α - 1 - 酸性糖蛋白。西替利嗪对所研究的免疫参数没有影响；当与先前显示其他化合物（如酮替芬和茶碱）对免疫反应有抑制作用的报告相关，以及与最近关于西替利嗪对嗜酸性粒细胞 ICAM - 1 表达调节的数据相关时，这些数据具有临床相关性。西替利嗪不影响淋巴细胞膜上 ICAM - 1 的表达。
